A methodology guide to identifying friction points between diagnosis and persistent therapy — and the launch decisions that follow from them.
Executive Summary (TL;DR)
The Friction Reality: Most pharma 'patient journey maps' stop at the prescription. The valuable territory is the 7–9 friction points between symptom recognition and persistent therapy where brands routinely lose addressable patients.
The Mapping Mechanism: Patient journey mapping done well combines patient interviews, claims data, HCP qualitative research, and digital ethnography to surface friction points the brand can actually address.
The Competitive Imperative: Brands that resource journey mapping at pre-launch routinely overshoot forecasts by addressing friction competitors leave intact — the work compounds across the product lifecycle.
Pharma & Life Sciences Practice • Brand Strategy Intelligence
Fig 1. Authority anchored in scientific rigour now defines pharma brand credibility.
Most pharma launches in India still get planned around the prescription event as the goal — the moment a physician writes a script. Patient journey mapping reveals why this framing leaves significant addressable opportunity unrealised. The patient does not walk into a clinic and walk out on therapy; that journey contains seven to nine distinct friction points, and addressable patients drop out at every one. Brands that map these friction points build launches that perform; brands that do not keep wondering why their forecasts overshoot the achievable.
What has changed in 2026 is that the data infrastructure to do this work properly finally exists in the Indian market. Hospital claims aggregators, pharmacy refill databases, patient digital ethnography, and AI-assisted qualitative coding now make it operationally feasible to build a journey map grounded in evidence rather than market-research intuition. The brands using these tools to redesign their launch strategies are uncovering friction points that competitor brands have been losing patients to for years — and converting that visibility into measurable share gain.
Patient journey mapping is not the linear funnel diagram that consumer marketing teaches. In a pharma context, the journey is non-linear, multi-stakeholder, and strongly shaped by access economics. A strong map captures the patient’s actual lived experience — not a brand-team idealisation of it.
The methodology rests on triangulating four distinct evidence streams:
Furthermore, a defensible map distinguishes between addressable and structural friction. A diagnostic delay caused by symptom non-specificity is structural; the brand cannot fix it. A diagnostic delay caused by GP referral confusion is addressable through CME and disease-state education. The map’s value is in flagging which friction points the brand can reasonably influence — and at what cost.
"Indian patients with chronic disease experience an average of 7 diagnosis-to-therapy delays before persistent treatment. Each delay is a friction point where addressable patients drop out — and where launch strategy can intervene."
Across Indian therapy areas, certain friction points appear consistently yet remain under-mapped. Identifying these before commissioning original research is critical for launch precision.
The journey map’s most useful output is the touchpoint inventory. Each sequenced interaction between the patient and the healthcare system represents a potential intervention point for launch strategy.
The diagnostic set typically spans multiple GP visits and tests. In 7–12 minute consultation windows, the brand’s influence is indirect—exerted through HCP education and decision-support tools. Treatment selection is further shaped by CME exposure and KOL-influenced clinical opinion. This is where medical affairs work—substantiation libraries and DOL-mediated communication—moves share-of-prescription.
Most launch teams under-resource persistence touchpoints. Refill prompts and dose-titration support require specific patient support infrastructure that pays back over a 12–24 month therapy window. Brands that treat persistence as a patient services problem rather than a marketing problem outperform on lifetime patient value.
Explore how OneAlphaMed integrates patient journey mapping into brand strategy and product launch planning to redesign launch resourcing around the friction that matters.
A patient journey map is operationally useless until it changes launch decisions. The translation step is where most pharma teams fail — commissioning the mapping work only to revert to a generic launch plan. Strategic success requires the map to reshape three core areas:
Launch measurement that stops at the script systematically underestimates strategy quality. Strong launches are distinguished by metrics that operate further down the patient journey.
Time-to-diagnosis is the critical leading indicator. If investments in diagnostic tools are working, the average time from symptom to specialist should compress measurably. Furthermore, 12-month persistence separates launches that built durable share from those that merely bought initial trial. Leakage at this stage, visible through pharmacy refill data, often goes unnoticed by teams focused only on new patient starts.
Finally, patient-reported friction reduction closes the loop. Comparing friction points in the brand’s footprint versus non-footprint markets is the strongest evidence that journey-mapping produced actual patient outcome changes rather than just internal alignment.
Patient journey mapping distinguishes pharma launches that perform from those that just execute. The brands investing in journey-grounded strategy in 2026 are addressing friction their competitors have ignored for years — and converting that asymmetry into share gain that compounds across the product lifecycle.
The launches cited in 2030 case studies will be the ones that put patient lived experience at the centre of resourcing decisions. The teams making that shift now are building the analytic muscle — and the patient-outcome evidence — their competitors will spend the rest of the decade trying to replicate.
OneAlphaMed integrates patient journey mapping into pre-launch strategy to redesign brand resourcing around the friction that drives patient outcomes. Explore our brand strategy and product launch services →
Patient journey mapping is a methodology that documents the patient's lived experience from symptom onset through diagnosis, treatment selection, and long-term therapy. The work identifies friction points where addressable patients drop out of the treatment pathway. The output reshapes pharma launch strategy by focusing resources on the points where the brand can actually influence patient outcomes.
A marketing funnel models linear progression from awareness to conversion. A patient journey map captures non-linear, multi-stakeholder pathways where access economics, HCP referral patterns, and persistence behaviour matter as much as awareness. The journey extends well beyond the prescription event — initial fill, refill, persistence, and switching all sit inside the map.
A defensible patient journey map triangulates four data sources. Structured patient interviews capture the lived chronology. Claims and pharmacy data reveal actual transition rates. HCP qualitative research captures prescribing logic. Digital ethnography on patient communities surfaces unstated barriers. Single-source maps tend to miss friction points that only become visible when these streams are cross-referenced.
Patient journey mapping is most valuable in the pre-launch window — typically 12–18 months before commercial launch. Earlier than that, the therapeutic profile is too uncertain to map against. Later than that, the launch plan is locked and findings cannot reshape resourcing. Mature launch teams refresh the map post-launch at 12-month intervals to validate friction reduction.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.
